Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ETON Stock Forecast 2025-2026
$16.26
Current Price
$436.05M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ETON Price Targets
+115.3%
To High Target of $35.00
+78.4%
To Median Target of $29.00
+59.9%
To Low Target of $26.00
ETON Price Momentum
+0.7%
1 Week Change
-3.8%
1 Month Change
+27.0%
1 Year Change
+22.1%
Year-to-Date Change
-29.3%
From 52W High of $23.00
+46.6%
From 52W Low of $11.09
📊 TOP ANALYST CALLS
Did ETON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eton Pharmaceuticals is one of their latest high-conviction picks.
Latest ETON Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ETON has a bullish consensus with a median price target of $29.00 (ranging from $26.00 to $35.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $16.26, the median forecast implies a 78.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 115.3% upside. Conversely, the most conservative target is provided by Madison El-Saadi at B. Riley Securities, suggesting a 59.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ETON Analyst Ratings
3
Buy
0
Hold
0
Sell
ETON Price Target Range
Low
$26.00
Average
$29.00
High
$35.00
Current: $16.26
Latest ETON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ETON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $35.00 |
| May 16, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Reiterates | $26.00 |
| May 14, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $28.00 |
| Mar 19, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Reiterates | $24.00 |
| Mar 19, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $26.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $33.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $33.00 |
| Jan 10, 2025 | B. Riley Securities | Madison El-Saadi | Buy | Initiates | $21.00 |
| Jan 8, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $18.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $17.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $15.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $11.00 |
| Oct 28, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $15.00 |
| Oct 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $11.00 |
| Oct 4, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $10.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $9.00 |
| May 6, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $8.00 |
| Dec 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| Jul 3, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $9.00 |
Eton Pharmaceuticals Inc. (ETON) Competitors
The following stocks are similar to Eton Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ETON
Eton Pharmaceuticals
mkt cap
436.05M
Eton Pharmaceuticals Inc. (ETON) Financial Data
Eton Pharmaceuticals Inc. has a market capitalization of $436.05M with a P/E ratio of 124.0x. The company generates $70.32M in trailing twelve-month revenue with a -9.5% profit margin.
Revenue growth is +117.5% quarter-over-quarter, while maintaining an operating margin of -0.2% and return on equity of -34.2%.
Valuation Metrics
Market Cap
$436.05M
Enterprise Value
$436.25M
P/E Ratio
124.0x
PEG Ratio
-0.3x
Price/Sales
6.4x
Growth & Margins
Revenue Growth (YoY)
+117.5%
Gross Margin
+35.0%
Operating Margin
-0.2%
Net Margin
-9.5%
EPS Growth
+117.5%
Financial Health
Cash/Price Ratio
+8.5%
Current Ratio
1.6x
Debt/Equity
133.5x
ROE
-34.2%
ROA
+1.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eton Pharmaceuticals Inc. (ETON) Business Model
About Eton Pharmaceuticals Inc.
What They Do
Develops innovative prescription pharmaceutical products.
Business Model
Eton Pharmaceuticals focuses on reformulating existing drugs to meet unmet medical needs, particularly in rare diseases and niche therapy areas. The company generates revenue through the commercialization of these enhanced prescription products, targeting specific medical fields such as endocrinology, oncology, and neurology.
Additional Information
Established in the United States, Eton plays a vital role in the healthcare sector, providing solutions for conditions often neglected by larger pharmaceutical firms. The company emphasizes strategic partnerships and serves underserved patient populations, contributing to the diversification and innovation of treatment options in the industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
31
CEO
Mr. Sean E. Brynjelsen
Country
United States
IPO Year
2018
Website
www.etonpharma.comEton Pharmaceuticals Inc. (ETON) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
Dec 04, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
12 days ago
Quick Summary
Eton Pharmaceuticals will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 4, 2025, at 9:30 AM ET in NYC. Investors can schedule 1x1 meetings.
Why It Matters
Eton Pharmaceuticals' participation in a major healthcare conference signals potential investor interest and market visibility, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
24 days ago
Quick Summary
Eton Pharmaceuticals will host 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, focusing on rare disease treatments.
Why It Matters
Eton Pharmaceuticals' participation in a major investor conference highlights its commitment to engaging with stakeholders, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals, Inc. will hold its Q3 2025 earnings call on November 6, 2025, at 4:30 PM EST, featuring key executives and analysts from multiple firms.
Why It Matters
The earnings call provides insights into Eton Pharmaceuticals' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals reported Q3 2025 product sales of $22.5M, up 129% YoY. GAAP EPS at $(0.07), non-GAAP EPS at $0.04. Adjusted EBITDA was $2.9M. Cash generated from operations totaled $12.0M.
Why It Matters
Eton Pharmaceuticals' strong Q3 2025 sales growth and positive FDA developments signal robust market potential, enhancing investor confidence and indicating future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eton Pharmaceuticals reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.13, while compared to earnings of $0.02 per share a year earlier.
Why It Matters
Eton Pharmaceuticals' quarterly loss exceeds estimates, indicating potential operational issues and declining performance compared to last year, which may negatively impact investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
1 month ago
Quick Summary
Eton Pharmaceuticals will report its Q3 2025 financial results on November 6, 2025. The company focuses on treatments for rare diseases.
Why It Matters
Eton Pharmaceuticals' upcoming Q3 2025 financial results may reveal insights into its growth and performance, influencing stock price and investor sentiment regarding its future potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ETON Stock
What is Eton Pharmaceuticals Inc.'s (ETON) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Eton Pharmaceuticals Inc. (ETON) has a median price target of $29.00. The highest price target is $35.00 and the lowest is $26.00.
Is ETON stock a good investment in 2026?
According to current analyst ratings, ETON has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ETON stock?
Wall Street analysts predict ETON stock could reach $29.00 in the next 12 months. This represents a 78.4% increase from the current price of $16.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eton Pharmaceuticals Inc.'s business model?
Eton Pharmaceuticals focuses on reformulating existing drugs to meet unmet medical needs, particularly in rare diseases and niche therapy areas. The company generates revenue through the commercialization of these enhanced prescription products, targeting specific medical fields such as endocrinology, oncology, and neurology.
What is the highest forecasted price for ETON Eton Pharmaceuticals Inc.?
The highest price target for ETON is $35.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 115.3% increase from the current price of $16.26.
What is the lowest forecasted price for ETON Eton Pharmaceuticals Inc.?
The lowest price target for ETON is $26.00 from Madison El-Saadi at B. Riley Securities, which represents a 59.9% increase from the current price of $16.26.
What is the overall ETON consensus from analysts for Eton Pharmaceuticals Inc.?
The overall analyst consensus for ETON is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $29.00.
How accurate are ETON stock price projections?
Stock price projections, including those for Eton Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:40 AM UTC